MapLight Therapeutics
Redwood City, CA · Biotechnology, Health Care, Therapeutics · 35 employees
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Funding history
- Funding Round — $188.2M — Jul 2025
- Series series d — $372.5M — Jul 2025
- Funding Round — $105.0M — Nov 2023
- Series series c — $225.0M — Oct 2023
- Funding Round — $50.0M — Jul 2023
Recent signals
- Jan 09, 2026: SEC 8-K (2.02): On January 9, 2026, MapLight Therapeutics, Inc. disclosed preliminary financial information for the fiscal year ended December 31, 2025, indicating that the Company had approximately $450 million in cash and cash equivalents. This unaudited figure is subject to change as it is a preliminary estimate based on currently available information and not final until the completion of the financial closing procedures. The event date marks the release of significant financial data relevant to investors, providing insights into the Company's liquidity position as it moves into the new fiscal year.
- Jul 28, 2025: Raised $188.2M
- Jul 28, 2025: Raised $372.5M in Series series d
- Mar 18, 2024: MapLight Therapeutics Appoints Vishwas Setia as Chief Financial Officer and Jonathan Gillis as Chief Administrative and Accounting Officer
- Nov 03, 2023: Raised $105.0M
- Oct 30, 2023: Raised $225.0M in Series series c
- Jul 19, 2023: Raised $50.0M
- Nov 10, 2022: Raised $12.0M
See plans & pricing → Track MapLight Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.